The PNP Technology

Summary of the E. coli PNP System

• Targets all solid tumors (ovarian, lymphoma, colon, brain, liver, prostate, pancreatic)
• Novel mechanism of cell kill resulting from inhibition of RNA and protein synthesis
• Active against both dividing and non-dividing tumor cells
• Excellent in vivo “bystander activity”
• Additive or synergistic with radiation therapy
• Excellent activity with a FDA approved drug, fludarabine phosphate
• Effectiveness proven in numerous mouse models of human cancers Safety/pharmacology demonstrated in preclinical studies
• Both vector and fludarabine phosphate are known to be safe and well tolerated in humans
• Validated by external laboratories
• Promising efficacy results observed in phase I clinical trial, without toxicity
• Potentially as effective as surgery or radiation therapy, but with less morbidity